Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027

Summary by The Manila Times
SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study...

1 Articles

The Manila TimesThe Manila Times
Lean Right

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027

SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study...

·Manila, Philippines (the)
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Manila Times broke the news in Manila, Philippines (the) on Tuesday, March 17, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Suzhou, China icon

Suzhou, China

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal